AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19026248 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine CR 25 mg
Number of subjects: 525
Study 19026248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 525
Study 16772525 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxia (100% oxygen) during isometric exercise
Number of subjects: 12
Study 16772525 — intervention group
Group type: COMPARATOR
Intervention: Normoxia (21% oxygen) during isometric exercise
Number of subjects: 12
Study 16772525 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxia (100% oxygen) at rest
Number of subjects: 12
Study 16772525 — intervention group
Group type: EXPERIMENTAL
Intervention: Postexercise circulatory arrest (PE-CA) after isometric exercise in hyperoxia
Number of subjects: 12
Study 14704300 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (160 mg of ferrous sulfate, 50 mg elemental iron, twice daily; total of 320 mg ferrous sulfate, 100 mg elemental iron daily)
Number of subjects: 26
Study 14704300 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 26
Study 14704300 — intervention group
Group type: EXPERIMENTAL
Intervention: Average American diet (AAD)
Number of subjects: 26
Study 14704300 — intervention group
Group type: EXPERIMENTAL
Intervention: Step 2 diet
Number of subjects: 26
Study 11379897 — intervention group
Group type: EXPERIMENTAL
Intervention: self-care/NSAID
Number of subjects: 69
Study 11379897 — intervention group
Group type: EXPERIMENTAL
Intervention: occlusal appliance/jaw mobilization + self-care/NSAID
Number of subjects: 69
Study 11379897 — intervention group
Group type: COMPARATOR
Intervention: control group
Number of subjects: 69
Study 9366499 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone propionate (200mg TP)
Number of subjects: 12
Study 9366499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 10172265 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis
Number of subjects: 0
Study 2424341 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic corticosteroid and/or antihistamine pretreatment
Number of subjects: 50
Study 2424341 — intervention group
Group type: COMPARATOR
Intervention: No pretreatment
Number of subjects: 50
Study 2424341 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic corticosteroid pretreatment
Number of subjects: 50
Study 29406184 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV)
Number of subjects: 201
Study 29406184 — intervention group
Group type: COMPARATOR
Intervention: Face mask
Number of subjects: 201
Study 29406184 — intervention group
Group type: COMPARATOR
Intervention: Face mask (in patients treated by NIV prior to randomisation)
Number of subjects: 201
Study 27321986 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based teaching via the Orpheus simulator (n = 9)
Number of subjects: 17
Study 27321986 — intervention group
Group type: COMPARATOR
Intervention: Lecture-based teaching (n = 8)
Number of subjects: 17
Study 24730564 — intervention group
Group type: EXPERIMENTAL
Intervention: Descriptive norm message
Number of subjects: 1020
Study 24730564 — intervention group
Group type: EXPERIMENTAL
Intervention: Injunctive norm message
Number of subjects: 1020
Study 24730564 — intervention group
Group type: EXPERIMENTAL
Intervention: Descriptive and injunctive norm message
Number of subjects: 1020
Study 24730564 — intervention group
Group type: COMPARATOR
Intervention: Control messages (two types)
Number of subjects: 1020
Study 23462072 — intervention group
Group type: EXPERIMENTAL
Intervention: Geographically targeted AdWords
Number of subjects: 0
Study 23462072 — intervention group
Group type: COMPARATOR
Intervention: Adverts placed on local websites
Number of subjects: 0
Study 23462072 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (AdWords and local website links)
Number of subjects: 0
Study 23462072 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 0
Study 20837662 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive dual-task training (five sessions, spaced at least 2 days apart)
Number of subjects: 20
Study 20837662 — intervention group
Group type: COMPARATOR
Intervention: Control group (untrained)
Number of subjects: 20
Study 18227177 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin >=4 g/day
Number of subjects: 246
Study 18227177 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin <4 g/day
Number of subjects: 246
Study 18227177 — intervention group
Group type: COMPARATOR
Intervention: Linezolid
Number of subjects: 246
Study 15624093 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-25% of total energy derived from fat
Number of subjects: 25
Study 15624093 — intervention group
Group type: COMPARATOR
Intervention: 40-45% of total energy derived from fat
Number of subjects: 25
Study 12679620 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral neurostimulation by posterior tibial nerve stimulation using a Stoller Afferent Nerve Stimulator (UroSurge, Coralville, Iowa, USA). Stimulation parameters: 0.5-10 mA, 200 micros, 20 Hz, performed every other day for 4 weeks.
Number of subjects: 32
Study 10232634 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinol (7576 retinol equivalents or 25000 IU)
Number of subjects: 2297
Study 10232634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2297
Study 8610833 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 20
Study 8610833 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 20
Study 1932300 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard IVIG (Sandoglobulin, 0.1 mg/kg IgM)
Number of subjects: 2
Study 1932300 — intervention group
Group type: EXPERIMENTAL
Intervention: IgM-enriched IVIG (Pentaglobin, 30 mg/kg IgM)
Number of subjects: 2
Study 6361988 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acyclovir
Number of subjects: 2
Study 6361988 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 6361988 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acyclovir
Number of subjects: 2
Study 6361988 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir (active)
Number of subjects: 2
Study 6361988 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir prodrug (BW 134U)
Number of subjects: 2
Study 30789491 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led motivational telephone follow-up
Number of subjects: 294
Study 28193267 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-contrast-enhanced computed tomography (nCT)
Number of subjects: 566
Study 28193267 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound sonography (US)
Number of subjects: 566
Study 27221237 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-faceted intervention including antenatal corticosteroids (ACS)
Number of subjects: 0
Study 27221237 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 0
Study 24384505 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS (right prefrontal‐‐anodal, left supraorbital‐‐cathodal) for 20 min at 1 mA current intensity
Number of subjects: 74
Study 24384505 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 74
Study 22397986 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with postthoracotomy pain (75 patients)
Number of subjects: 110
Study 22397986 — intervention group
Group type: COMPARATOR
Intervention: Patients without postthoracotomy pain (35 patients)
Number of subjects: 110
Study 19411614 — intervention group
Group type: EXPERIMENTAL
Intervention: Active drug treatment (exact drug not specified)
Number of subjects: 0
Study 19411614 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressing cohort
Number of subjects: 0
Study 19411614 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonprogressing cohort
Number of subjects: 0
Study 19411614 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline elevated triglycerides
Number of subjects: 0
Study 19411614 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline decreased peroneal motor NCV
Number of subjects: 0
Study 17679784 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan 16 mg
Number of subjects: 0
Study 17679784 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15658650 — intervention group
Group type: EXPERIMENTAL
Intervention: Decoction of Qingre Huoxue recipe (QHR) given one dose per day in addition to standard treatment.
Number of subjects: 32
Study 15658650 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment including impact therapy of methyl-prednisolone followed by oral prednisone, with additional cyclophosphamide or mycophenolate mofetil for some patients.
Number of subjects: 32
Study 11699672 — intervention group
Group type: EXPERIMENTAL
Intervention: High Affect Mirroring (HAM) group
Number of subjects: 41
Study 11699672 — intervention group
Group type: COMPARATOR
Intervention: Low Affect Mirroring (LAM) group
Number of subjects: 41
Study 9021434 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic ibuprofen (400 mg)
Number of subjects: 0
Study 9021434 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen (100 mg)
Number of subjects: 0
Study 9021434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8206111 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine, 120 mg p.o.
Number of subjects: 36
Study 8206111 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine, 10 micrograms/kg i.v.
Number of subjects: 36
Study 8206111 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine, 12.5 micrograms/kg i.v.
Number of subjects: 36
Study 8206111 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine, 120 mg p.o. (GHRH stimulated)
Number of subjects: 36
Study 8206111 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine, 10 micrograms/kg i.v. (GHRH stimulated)
Number of subjects: 36
Study 8206111 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine, 12.5 micrograms/kg i.v. (GHRH stimulated)
Number of subjects: 36
Study 3382764 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen at a dose of 10 mg twice daily
Number of subjects: 60
Study 3382764 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone at a dose of 5 mg twice a day
Number of subjects: 60
Study 3382764 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian irradiation
Number of subjects: 60
Study 30467695 — intervention group
Group type: EXPERIMENTAL
Intervention: Niaoduqing Particles (5 g thrice daily and 10 g before bedtime for 24 weeks)
Number of subjects: 292
Study 30467695 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 292
Study 30467695 — intervention group
Group type: EXPERIMENTAL
Intervention: Niaoduqing Particles (after open-label treatment)
Number of subjects: 292
Study 30467695 — intervention group
Group type: COMPARATOR
Intervention: Placebo (after open-label treatment)
Number of subjects: 292
Study 30467695 — intervention group
Group type: EXPERIMENTAL
Intervention: Niaoduqing Particles
Number of subjects: 292
Study 30467695 — intervention group
Group type: EXPERIMENTAL
Intervention: Niaoduqing Particles (projected long-term effect)
Number of subjects: 292
Study 28460246 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (COPE)
Number of subjects: 51
Study 25857594 — intervention group
Group type: EXPERIMENTAL
Intervention: Tratinterol hydrochloride tablets
Number of subjects: 223
Study 25857594 — intervention group
Group type: COMPARATOR
Intervention: Procaterol hydrochloride tablets (control)
Number of subjects: 223
Study 23435521 — intervention group
Group type: EXPERIMENTAL
Intervention: C‐Port xA® System
Number of subjects: 71
Study 23435521 — intervention group
Group type: COMPARATOR
Intervention: Hand-sewn technique
Number of subjects: 71
Study 23435521 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 71
Study 21649522 — intervention group
Group type: EXPERIMENTAL
Intervention: Bepotastine besilate ophthalmic solution 1.5%
Number of subjects: 107
Study 21649522 — intervention group
Group type: EXPERIMENTAL
Intervention: Bepotastine besilate ophthalmic solution 1.0%
Number of subjects: 107
Study 21649522 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 18164473 — intervention group
Group type: EXPERIMENTAL
Intervention: Various nonsurgical interventions for CLBP
Number of subjects: 0
Study 18164473 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 0
Study 15141794 — intervention group
Group type: COMPARATOR
Intervention: Bag-valve device
Number of subjects: 104
Study 15141794 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxylator
Number of subjects: 104
Study 11890637 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly iron supplementation
Number of subjects: 137
Study 11890637 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation during menstruation
Number of subjects: 137
Study 11890637 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study 10360290 — intervention group
Group type: EXPERIMENTAL
Intervention: LASIK
Number of subjects: 286
Study 10360290 — intervention group
Group type: COMPARATOR
Intervention: PRK
Number of subjects: 286
Study 10360290 — intervention group
Group type: COMPARATOR
Intervention: ASPRK
Number of subjects: 286
Study 7812991 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg oral clomipramine daily
Number of subjects: 33
Study 7812991 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg oral clomipramine daily
Number of subjects: 33
Study 2696914 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryosurgery
Number of subjects: 16
Study 2696914 — intervention group
Group type: COMPARATOR
Intervention: Conventional Surgery
Number of subjects: 16
Study 65126 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune serum globulin (20 ml)
Number of subjects: 195
Study 65126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195
Study 31567325 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal Drug Delivery Systems (IDDS)
Number of subjects: 1403
Study 30574857 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (test group, n=20)
Number of subjects: 40
Study 30574857 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group, n=20)
Number of subjects: 40
Study 29714858 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed umbilical cord clamping after pulsation loss
Number of subjects: 338
Study 29714858 — intervention group
Group type: COMPARATOR
Intervention: Early clamping within 60 seconds after birth
Number of subjects: 338
Study 25069638 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 198
Study 23234632 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab (180 mg subcutaneous every 4 weeks)
Number of subjects: 50
Study 23234632 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab (180 mg subcutaneous every 12 weeks)
Number of subjects: 50
Study 23234632 — intervention group
Group type: COMPARATOR
Intervention: Intravenous bisphosphonates
Number of subjects: 50
Study 21319139 — intervention group
Group type: EXPERIMENTAL
Intervention: Tecnis Z9003 IOL
Number of subjects: 60
Study 21319139 — intervention group
Group type: COMPARATOR
Intervention: AR40e IOL
Number of subjects: 60
Study 18812411 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilience-enhancing programme in Health Promoting Schools (HPS)
Number of subjects: 5510
Study 18812411 — intervention group
Group type: COMPARATOR
Intervention: Non-Health Promoting Schools (non-HPS)
Number of subjects: 5510
Study 16886144 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole
Number of subjects: 39
Study 16886144 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole and Rifampin
Number of subjects: 39
Study 15539971 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors and beta blockers
Number of subjects: 0
Study 15539971 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldosterone blocking agents
Number of subjects: 0
Study 15539971 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blockers
Number of subjects: 0
Study 12498513 — intervention group
Group type: EXPERIMENTAL
Intervention: Pycnogenol
Number of subjects: 1289
Study 12498513 — intervention group
Group type: COMPARATOR
Intervention: Calcium dobesilate
Number of subjects: 1289
Study 12498513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1289
Study 9646192 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate 240 mg twice daily
Number of subjects: 194
Study 9646192 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 194
Study 9646192 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate 120 mg nightly
Number of subjects: 194
Study 9646192 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg nightly
Number of subjects: 194
Study 9646192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 194
Study 8252890 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 92
Study 8252890 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 92
Study 3612896 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal (10 g as SuperCharR suspension) administered 2 hr prior, and at 0, 2, 6, and 8 hr after tobramycin administration.
Number of subjects: 5
Study 3612896 — intervention group
Group type: COMPARATOR
Intervention: Control group (no activated charcoal treatment).
Number of subjects: 5
Study 31199180 — intervention group
Group type: EXPERIMENTAL
Intervention: belimumab 10 mg/kg
Number of subjects: 60
Study 31199180 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study 28685495 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg rosuvastatin combined with 10 mg metformin (T1)
Number of subjects: 18
Study 28685495 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg rosuvastatin combined with 50 mg metformin (T2)
Number of subjects: 18
Study 28685495 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg rosuvastatin combined with 500 mg metformin (T3)
Number of subjects: 18
Study 28685495 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg rosuvastatin combined with 1 mg furosemide (T4)
Number of subjects: 18
Study 28685495 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg rosuvastatin combined with 5 mg furosemide (T5)
Number of subjects: 18
Study 27782861 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (eight pragmatic Traditional Chinese Medicine treatments over 4 weeks)
Number of subjects: 15
Study 27782861 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 15
Study 24650076 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeding tubes in nursing home residents with cognitive impairment
Number of subjects: 3479
Study 22079009 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal screening test offer
Number of subjects: 111
Study 22079009 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling regarding the meaning of testing
Number of subjects: 111
Study 20572421 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise (MAE)
Number of subjects: 48
Study 20572421 — intervention group
Group type: COMPARATOR
Intervention: Control (CTR)
Number of subjects: 48
Study 20572421 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity aerobic exercise (HAE)
Number of subjects: 48
Study 20572421 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity resistance exercise (MRE)
Number of subjects: 48
Study 18242413 — intervention group
Group type: EXPERIMENTAL
Intervention: Romiplostim (subcutaneous injections, adjusted doses to maintain platelet counts of 50x10(9)/L to 200x10(9)/L)
Number of subjects: 125
Study 18242413 — intervention group
Group type: EXPERIMENTAL
Intervention: Romiplostim
Number of subjects: 125
Study 18242413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 16270114 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral intervention (five-contact, eight-week intervention)
Number of subjects: 124
Study 16270114 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 124
Study 11860969 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% pilocarpine
Number of subjects: 20
Study 11860969 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% pilocarpine
Number of subjects: 20
Study 11860969 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.0313% pilocarpine
Number of subjects: 20
Study 11860969 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.0625% pilocarpine
Number of subjects: 20
Study 10199862 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (50 microgram/day)
Number of subjects: 18
Study 7598670 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive social behavior
Number of subjects: 64
Study 7598670 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative social behavior
Number of subjects: 64
Study 2162867 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibre-containing feed (Enrich)
Number of subjects: 91
Study 2162867 — intervention group
Group type: COMPARATOR
Intervention: Fibre-free feed (Ensure)
Number of subjects: 91
Study 20671 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg flunitrazepam
Number of subjects: 0
Study 20671 — intervention group
Group type: COMPARATOR
Intervention: diazepam
Number of subjects: 0
Study 20671 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 0
Study 30239421 — intervention group
Group type: EXPERIMENTAL
Intervention: Late peak of HMGB1
Number of subjects: 210
Study 30239421 — intervention group
Group type: EXPERIMENTAL
Intervention: Late peak of HMGB1 with inflammatory disease
Number of subjects: 210
Study 28622891 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted neck dissection (38 patients)
Number of subjects: 113
Study 28622891 — intervention group
Group type: COMPARATOR
Intervention: Conventional neck dissection (75 patients)
Number of subjects: 113
Study 25624387 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2‐0.5 mg/kg oral morphine
Number of subjects: 91
Study 25624387 — intervention group
Group type: COMPARATOR
Intervention: 10 mg/kg of oral ibuprofen
Number of subjects: 91
Study 23520456 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher completed level of schooling (intervention group)
Number of subjects: 986